NCT04532866 (BRAIVE) is a NA clinical trial of Isolation and Confinement in Isolation, Social, sponsored by Charite University, Berlin, Germany.

Who is sponsoring NCT04532866?

NCT04532866 is sponsored by Charite University, Berlin, Germany.

What drugs are being tested in NCT04532866?

Interventions in NCT04532866: Isolation and Confinement.

What condition does NCT04532866 study?

NCT04532866 studies Isolation, Social, Virtual Reality, Spatial Navigation.

Is NCT04532866 still recruiting?

NCT04532866 is currently status unknown. Last updated 30 August 2023.

Last reviewed 2023-08-30 · How we verify

NCT04532866: BRAIVE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Brain Changes in Response to Long-Duration Isolation and Confinement

Status unknown NA Last updated 30 August 2023

What this trial tests

NA trial testing Isolation and Confinement in Isolation, Social in 16 participants. Status unknown.

Timeline

14 September 2021

Primary endpoint
30 October 2022

30 June 2024

Quick facts

Lead sponsor	Charite University, Berlin, Germany
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	16
Start date	14 September 2021
Primary completion	30 October 2022
Estimated completion	30 June 2024
Sites	1 location across Russia

Drugs / interventions tested

Isolation and Confinement

Conditions studied

Isolation, Social — all drugs for Isolation, Social →
Virtual Reality — all drugs for Virtual Reality →
Spatial Navigation — all drugs for Spatial Navigation →

Sponsor

Charite University, Berlin, Germany

Who can join

Adults 28 to 55, any sex, with Isolation, Social or Virtual Reality. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study investigates the time course and magnitude of eight months of isolation and confinement in a spaceflight analog facility on brain changes and cognitive performance. The study also assesses the feasibility of an immersive and interactive virtual environment (VE) to enhance positive affect and mental well-being during prolonged isolation and confinement.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Charite University, Berlin, Germany trials

Trials by the same sponsor.

NCT07486167 — Influence of Lung Volume Optimization Maneuver on Cardiac Output and Lung Compliance in Ventilated Children With Congeni · Phase 1, PHASE2 · not yet recruiting
NCT07476729 — International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) · Phase 3 · not yet recruiting
NCT07503054 — Ovarian Cancer Screening and AI · NA · not yet recruiting
NCT07529197 — Observational Study on Immunoadsorption (IA) in Patients With Autoantibody-Positive Post-Infectious ME/CFS · recruiting
NCT07388693 — Feasibility of Integrating Olfactory Stimuli Into Virtual Reality Cue Exposure for Patients With Alcohol Dependence · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04532866 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Charite University, Berlin, Germany
Last refreshed: 30 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04532866.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing